Immunicum: Combination Trial with Keytruda Proceeds
Research Note
2020-06-15
10:00
Redeye views the safety update from the Phase Ib ILIAD trial as encouraging, allowing for a continuation of investigations into a combination with checkpoint inhibitors. We reiterate our base case of SEK 15.4.
NE
Niklas Elmhammer
Disclosures and disclaimers